|
Video: What is a Stock Split?
|
|
Evoke Pharma is a pharmaceutical company focused primarily on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. Co. is focused on developing its primary product, Gimoti (metoclopramide) nasal spray. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide providing delivery by nasal spray administration. Co. is party to a commercial services agreement with Eversana Life Science Services, LLC, or Eversana, pursuant to which Eversana commercializes and distributes Gimoti in the U.S. According to our EVOK split history records, Evoke Pharma has had 1 split. | |
|
Evoke Pharma (EVOK) has 1 split in our EVOK split history database. The split for EVOK took place on May 23, 2022. This was a 1 for 12 reverse split, meaning for each 12 shares of EVOK owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 83.3333333333333 share position following the split.
When a company such as Evoke Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the EVOK split history from start to finish, an original position size of 1000 shares would have turned into 83.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Evoke Pharma shares, starting with a $10,000 purchase of EVOK, presented on a split-history-adjusted basis factoring in the complete EVOK split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$102.96 |
|
End price/share: |
$0.61 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.41% |
|
Average Annual Total Return: |
-40.13% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$59.25 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
05/23/2022 | 1 for 12 |
|
|